Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion
| Autor: | Albert J. Augustin, Francesco Bandello, Patricia Udaondo, Gabriel Coscas, Marc D. de Smet, Yossi Yatziv, Paolo Lanzetta, Giovanni Staurenghi, Elad Moisseiev, Maria Cristina Parravano, Anat Loewenstein, Gisèle Soubrane |
|---|---|
| Přispěvatelé: | Coscas, G, Augustin, A, Bandello, Francesco, de Smet, Md, Lanzetta, P, Staurenghi, G, Parravano, Mc, Udaondo, P, Moisseiev, E, Soubrane, G, Yatziv, Y, Loewenstein, A. |
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Retinal Vein Visual acuity genetic structures Visual Acuity Dexamethasone Macular Edema Retinal vein occlusion Ophthalmology Occlusion Retinal Vein Occlusion Medicine Humans Dexamethasone implant Fluorescein Angiography Macular edema Glucocorticoids Aged Retrospective Studies Aged 80 and over Drug Implants medicine.diagnostic_test business.industry Retrospective cohort study General Medicine Middle Aged medicine.disease Fluorescein angiography eye diseases Surgery Treatment Outcome Ozurdex Delayed-Action Preparations Retreatment Female medicine.symptom Injections Intraocular business Complication medicine.drug |
| Zdroj: | EUROPEAN JOURNAL OF OPHTHALMOLOGY r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname |
| ISSN: | 1724-6016 1120-6721 |
| Popis: | Purpose To review the current practice of retreatment with Ozurdex injections in patients with macular edema (ME) secondary to retinal vein occlusion (RVO), and to recommend simple guidelines for Ozurdex reinjection in management of RVO. Methods This was a multicenter retrospective study of patients who received more than 2 Ozurdex injections for the treatment of ME in RVO. Recorded parameters included percent of patients with a 15-letter gain, visual acuity (VA) improvement from baseline, change in central macular thickness (CMT), time to reinjection, and occurrence of any complications. Results A total of 128 patients were included, 58 (45.3%) with central RVO (CRVO) and 70 (54.7%) with branch RVO (BRVO). Mean interval for Ozurdex reinjection was 5.9 months following the first injection and 8.7 months following the second. A >15-letter gain in VA was observed in 34 (48.8%) patients with CRVO and 16 (28%) patients with BRVO. Mean overall VA improvement at month 6 did not show significance (p>0.05); however, a significantly better mean VA improvement was seen in treatment-naïve eyes (pConclusions Repeated injections of Ozurdex are effective and have a favorable safety profile. In current practice, the retreatment interval with Ozurdex injections might be too long, precluding the full therapeutic potential of this treatment modality. A strategy for managing RVO patients treated with Ozurdex on an as-needed basis is provided. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|